• Patients must understand and provide written informed consent before they can participate in the study. They must understand the study procedures of the trial and be willing to complete the required assessments;

• Male and female patients aged ≥ 18 years;

• SBS patients without colon in continuity:

• Patients with history of SBS resulting in intestinal failure caused by a major intestinal resection (e.g., injury, cancer, Crohn's disease, vascular disease, volvulus, intussusceptions or other causes). Diagnosis of SBS will be defined as remaining small bowel excluding colon in continuity and considered stable with regard to parenteral support (PS) need. Intestinal failure will be defined according to the recommendations of the American Society of Parenteral and Enteral Nutrition (ASPEN), i.e. a reduction of gut function below the minimum necessary for the absorption of macronutrients and/or water and electrolytes, such that intravenous (IV) supplementation is required to maintain health and/or growth;

• At least 6 months elapsed since last surgical bowel resection;

• No restorative surgery planned in the overall study period;

• Patients with at least 6 continuous months of PS dependency (parenteral nutrition and/or intravenous fluids) before entry in the study;

• Patients receiving stable PS (fluids, electrolytes or nutrients) at least three times per week to meet caloric, fluid or electrolytes needs with no major changes in provisions for at least 12 weeks;

• Patients with Crohn's disease will have to be in clinical remission for ≥ 12 weeks before entry in the study;

⁃ Patients must be able to ingest solid or semi-solid foods and drink fluids;

⁃ If female and of child-bearing potential, the patient use a highly effective method of birth control for the entire study duration. Highly effective birth control methods include: combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal, transdermal); progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable, implantable); intrauterine device (IUD); intrauterine hormone-releasing system (IUS); bilateral tubal occlusion; vasectomized partner; sexual abstinence;

⁃ If female and of child-bearing potential, the patient must have a negative urine pregnancy test prior the first administration of the study drugs;

⁃ Male patients must agree to use an acceptable form of birth control during the study and for 30 days after the last dose;

⁃ Satisfactory general health status as determined by the investigator based on medical history and physical examination